Analysts Swing to Diverse Views for Argos Therapeutics, Inc. (ARGS), DexCom, Inc. (DXCM)

Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) opened at $0.17, and ended -0.9% lower at $0.17. Nearly 2.43 million shares were traded by the close, lower than its average daily volume of 4.86 million shares.

Argos Therapeutics, Inc. (ARGS) Analyst Opinion

Argos Therapeutics, Inc. has a consensus hold rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 7.63% of shares outstanding. The stock spiked 4.95% last month and is up 10.2 this year. Wall Street is only getting neutral on the stock, with 0 of analysts who cover ARGS having a buy-equivalent rating. Analysts have placed a $0 price target on Argos Therapeutics, Inc., suggesting a -100% decline from recent close. It’s currently trading about -97.09% below its 52-week high.

Argos Therapeutics, Inc. Earnings Surprise

Argos Therapeutics, Inc. (ARGS) surprised the stock market in its last reported earnings when it earned -$0.13 a piece versus the consensus-estimated -$0.2. Its revenue totaled $100000 up 42.86% from the previous quarter.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Intraday View

This stock (ARGS) is ahead of its 52-week low with 26.18%. Its last month’s stock price volatility remained 8.87% which for the week stands at 8.88%. The share price has moved forward from its 20 days moving average, trading at a distance of 5.48% and stays -0.38% away from its 50 days moving average. Over the last five days, shares have faced -2.65% losses and now is down -40.2% since hitting its 200-day moving average of $0.2079. Argos Therapeutics, Inc. (ARGS) has made its way to a 12-month decline of -97.02%.

Turning to DexCom, Inc. (NASDAQ:DXCM), its shares were trading at $58.22 a retreat of $-0.38, on the trading floor. The stock, after opening at $58.99, touched a high of $59.18 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.1. DexCom, Inc. has 7 buy ratings, 6 holds and 0 sells even after the stock tumbled -34.44% from its high of $88.80 to a $5.05 billion market value through last close.

DexCom, Inc. (DXCM) Consensus Price Target

The company’s consensus rating on Reuter’s scale improved from 1.94 to 2.06 during a month. Analysts set a 12-month price target of $68.19 a share. The target implies a 17.12% spike from where the shares are currently trading. Also, the current price highlights a discount of 71.76% to analysts’ high consensus price target.

DexCom, Inc. (NASDAQ:DXCM) Intraday Trading

The counter witnessed a trading volume of 1.17 million shares versus an average volume of 1.64 million shares during last trading session. Its last month’s stock price volatility remained 5.73% which for the week approaches 3.59%. The lowest price the stock reached in the last trading day was $57.32 and compares with the $42.62 52-week low. The stock recovered 36.6% since its low point and has performed 1.45% year-to-date.

Previous articleWall Street Analyst Actions To Watch: Immunomedics, Inc. (IMMU), CARBO Ceramics Inc. (CRR)
Next articleVaried Analyst Comments On 22nd Century Group, Inc. (XXII), Depomed, Inc. (DEPO)